The current project, born within the ISCIII Cell Therapy Network (TerCel) and supported by the SCREN platform, proposes a multicenter randomized and controlled study to investigate the therapeutic use of mesenchymal stromal cells (MSC), either autologous or allogeneic, for knee osteoarthritis, a major health problem with unsatisfactory treatments. Our working hypothesis is that the intra-articular injection of the MSC has beneficial effects, which would be obtained by anti-inflammation, modulation of immune function and articular cartilage repair. This proposal is based on evidence obtained both in vitro and in animal experiments, both in the literature and our own experience obtained in preclinical work and in two recently published pilot studies that evidenced efficacy, both for autologous and allogeneic intra-articular treatments with MSC, without adverse effects. Based on the expertise of TerCel and SCREN In the present project we aim to bring this innovative therapy to the clinic. An homogeneous cell product with the same IMPD (from the Valladolid Group-MSV cells-) will be provided by the four Clean Rooms that participate in the project, with the experience of prior trials. This phase II-III, randomized and controlled trial will enrol 120 patients divided into three arms: a) active control (hyaluronic acid), b) autologous MSV, and c) allogeneic MSV. This structure will allow not only to compare each experimental arm to the active control, but also comparing directly autologous and allogeneic cells. The use of allogenic MSV increases the potential and universality of the treatment. Response assessment (1 year and extension to a second one) will be blind and will include the study of the evolution of algofunctional indexes and quality of life, and assessment of cartilage quality by advanced magnetic resonance imaging (T2 mapping relaxation), with a centralized analysis of the results.
artrosis
medicina regenerativa
terapia celular
células estromales mesenquimatosas
MSC
CEM
médula ósea
alogénico
alogénica
ensayo clínico
Acción Estratégica en Salud (AES)
01/01/2019 - 31/12/2022
SANCHEZ-GUIJO MARTIN, FERMIN
FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL)
Castilla y León
Salamanca
767,963 €